Literature DB >> 17309820

Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors.

Michael Rosu-Myles1, Barbara J Taylor, Linda Wolff.   

Abstract

OBJECTIVE: The tumor suppressor p15Ink4b (Ink4b) is a cell-cycle inhibitor that is inactivated in a high percentage of acute myeloid leukemia and myeloid dysplasia syndrome cases. Despite this, the role of Ink4b in hematopoiesis remains unclear. Here we examined the role of Ink4b in blood cell formation using Ink4b-deficient (Ink4b(-/-)) mice.
METHODS: We compared the bone marrow (BM) of Ink4b(-/-) and wild-type mice using flow cytometric, colony-forming unit and competitive repopulating assays (CRA). The proliferation, differentiation, self-renewal, and apoptosis of progenitor cells were further compared by in vitro and in vivo methods.
RESULTS: BM from Ink4b(-/-) mice contained increased numbers of granulocyte-monocyte progenitors and Gr-1(+) cells and showed a competitive advantage over wild-type cells in myeloid cell formation by CRA. Ink4b(-/-) progenitors did not demonstrate increased proliferation, self-renewing potential, or reduced apoptosis. Instead, Ink4b(-/-) common myeloid progenitors (CMPs) showed increased myeloid progenitor formation concomitant with reduced erythroid potential.
CONCLUSIONS: This work establishes a role for Ink4b in regulating the differentiation of CMPs and indicates that loss of Ink4b enhances the formation of myeloid progenitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17309820     DOI: 10.1016/j.exphem.2006.11.005

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  19 in total

1.  Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia.

Authors:  Juraj Bies; Marek Sramko; Joanna Fares; Michael Rosu-Myles; Steven Zhang; Richard Koller; Linda Wolff
Journal:  Blood       Date:  2010-05-10       Impact factor: 22.113

2.  The tumor suppressor p15Ink4b regulates the differentiation and maturation of conventional dendritic cells.

Authors:  Joanna Fares; Richard Koller; Rita Humeniuk; Linda Wolff; Juraj Bies
Journal:  Blood       Date:  2012-03-28       Impact factor: 22.113

3.  Meeting report: Seventh International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Annapolis, MD, May 13-16, 2007.

Authors:  Linda Wolff; Steven J Ackerman; Giuseppina Nucifora
Journal:  Exp Hematol       Date:  2008-03-04       Impact factor: 3.084

Review 4.  Epigenetic changes in the myelodysplastic syndrome.

Authors:  Jean-Pierre Issa
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

5.  Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.

Authors:  Xudong Wu; Ida Holst Bekker-Jensen; Jesper Christensen; Kasper Dindler Rasmussen; Simone Sidoli; Yan Qi; Yu Kong; Xi Wang; Yajuan Cui; Zhijian Xiao; Guogang Xu; Kristine Williams; Juri Rappsilber; Casper Kaae Sønderby; Ole Winther; Ole N Jensen; Kristian Helin
Journal:  Cell Res       Date:  2015-10-16       Impact factor: 25.617

6.  Brief report: Loss of p15Ink4b accelerates development of myeloid neoplasms in Nup98-HoxD13 transgenic mice.

Authors:  Rita Humeniuk; Richard Koller; Juraj Bies; Peter Aplan; Linda Wolff
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

7.  Hematopoietic stem cell function requires 12/15-lipoxygenase-dependent fatty acid metabolism.

Authors:  Michelle Kinder; Cong Wei; Suresh G Shelat; Mondira Kundu; Liang Zhao; Ian A Blair; Ellen Puré
Journal:  Blood       Date:  2010-03-31       Impact factor: 22.113

8.  Regulation of murine hematopoietic stem cell quiescence by Dmtf1.

Authors:  Michihiro Kobayashi; Edward F Srour
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

Review 9.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

Review 10.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.